

CLAIMS

sub a⁸

1. A composition for treating autism, comprising:
genomeceutical material of the type that affects
expression of a DPPIV like compounds when ingested by a
5 human in such a manner as to relieve symptoms of autism;
and

one or more of a protease, peptidase or phytase.

sub B¹⁴
10

2. The composition of claim 1, wherein said
genomeceutical material includes galactose.

3. The composition of claim 1, wherein said
genomeceutical material includes glucans.

sub a⁹
15

4. The composition of claim 1, wherein said
genomeceutical material includes a milk sugar other than
galactose.

sub B¹⁴
20

5. The composition of claim 1, wherein said DPPIV
like compound includes DPPIV or QPP.

6. The composition of claim 1, wherein said
protease includes at least one of an acid fast protease
and a cystein protease.

25

7. The composition of claim 6, wherein said cystein
protease is bromelain or papain.

sub a¹⁰
30

8. The composition of claim 1, comprising both a
protease and a phytase.

9. The composition of claims 1, further including
phospholipid promoting compound.

00072315-060101
TOT0905T922860

10. The composition of claims 1, further including a disaccharidase compound.

5 11. The composition of claims 1, further including a lipase compound.

12. A composition for treating autism, comprising:
a phytase like compound; and
10 one or more of a genomeceutical for treating autism
or a protease for treating autism.

add a"7

098720615-060101